Pridopidine, sebetralstat and mirdametinib, which are novel treatments that are yet to approved anywhere in the world, are among the latest products for which marketing applications are now under review by the European Medicines Agency.

Results from the top Japanese pharma firms in the fiscal first quarter were marked mainly by strong global performances for mainstay products and significant currency effects due to the continued weakness of the yen, although forex concerns are rising. Eisai's Alzheimer's drug Leqembi also gained momentum, particularly in the US. 

Leqembi for early Alzheimer’s, Skyclarys for Friedreich’s ataxia and Zurzuvae for postpartum depression meet or exceed Biogen’s internal sales expectations.

For Sage, the mid-stage failure of SAGE-324 in essential tremor is its second setback in a year full of clinical trial readouts. For Biogen, it highlights a lack of later-stage pipeline prospects.